%	O
%	O
TITLE	O

Logistic	O
regression	O
prediction	O
model	O
identify	O
type	O
2	O
diabetes	O
mellitus	O
as	O
a	O
prognostic	O
factor	O
for	O
human	O
papillomavirus	O
-	O
16	O
associated	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

%	O
%	O
ABSTRACT	O

HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
and	O
HPV	O
-	O
16	O
-	O
negative	O
HNSCC	O
have	O
different	O
clinical	O
factors	O
,	O
representing	O
distinct	O
forms	O
of	O
cancers	O
.	O

The	O
study	O
aimed	O
to	O
identify	O
patient	O
-	O
specific	O
factors	O
for	O
HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
based	O
on	O
baseline	O
clinical	O
data	O
.	O
Factors	O
associated	O
with	O
HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
were	O
identified	O
using	O
the	O
data	O
from	O
210	B-Study_Cohort
patients	I-Study_Cohort
diagnosed	I-Study_Cohort
with	I-Study_Cohort
HNSCC	I-Study_Cohort
at	O
University	O
College	O
of	O
London	B-Study_Location
Hospital	O
between	O
January	B-Study_Time
1	I-Study_Time
,	I-Study_Time
2003	I-Study_Time
,	I-Study_Time
and	I-Study_Time
April	I-Study_Time
30	I-Study_Time
,	I-Study_Time
2015	I-Study_Time
,	I-Study_Time
inclusive	O
.	O

A	O
series	O
of	O
models	O
were	O
developed	O
using	O
logistic	O
regression	O
methods	O
,	O
and	O
the	O
overall	O
model	O
fit	O
was	O
compared	O
using	O
Akaike	O
Information	O
Criterion	O
.	O

Survival	O
analysis	O
was	O
carried	O
with	O
Cox	O
proportional	O
hazards	O
model	O
for	O
survival	O
-	O
time	O
outcomes	O
.	O

The	O
survival	O
time	O
for	O
individual	O
patients	O
was	O
defined	O
as	O
the	O
time	O
from	O
diagnosis	O
of	O
HNSCC	O
to	O
the	O
date	O
of	O
death	O
from	O
any	O
cause	O
.	O

For	O
patients	O
who	O
did	O
not	O
die	O
,	O
they	O
were	O
censored	O
at	O
the	O
end	O
of	O
study	O
on	O
April	O
30	O
,	O
2015	O
.	O
Of	O
the	O
210	O
patients	O
,	O
151	O
(	O
72	O
%	O
)	O
were	O
found	O
to	O
have	O
HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
.	O

The	O
logistic	O
regression	O
model	O
showed	O
that	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
developing	O
HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
was	O
3	O
.	O
79	O
times	O
higher	O
in	O
patients	O
with	O
Type	O
2	O
Diabetes	O
Mellitus	O
(	O
T2DM	O
)	O
(	O
odd	O
ratio	O
[	O
OR	O
]	O
,	O
3	O
.	O
79	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
70	O
-	O
8	O
.	O

44	O
)	O
than	O
in	O
those	O
without	O
T2DM	O
,	O
and	O
8	O
.	O
84	O
times	O
higher	O
in	O
patients	O
with	O
history	O
of	O
primary	O
HNSCC	O
(	O
OR	O
,	O
8	O
.	O
84	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
30	O
-	O
33	O
.	O

88	O
)	O
than	O
in	O
those	O
without	O
a	O
history	O
of	O
primary	O
HNSCC	O
.	O

HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
was	O
also	O
observed	O
more	O
in	O
tonsils	O
(	O
OR	O
,	O
4	O
.	O
02	O
;	O
95	O
%	O
CL	O
,	O
1	O
.	O
56	O
-	O
10	O
.	O

36	O
)	O
and	O
less	O
in	O
non	O
-	O
alcohol	O
drinker	O
'	O
s	O
oral	O
cavity	O
(	O
OR	O
,	O
0	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
03	O
-	O
0	O
.	O
56	O
)	O
.	O

Furthermore	O
,	O
individual	O
patients	O
were	O
followed	O
-	O
up	O
for	O
1	O
to	O
13	O
years	O
(	O
median	O
of	O
1	O
year	O
)	O
.	O

Patients	O
with	O
HPV	O
-	O
positive	O
HNSCC	O
had	O
a	O
median	O
survival	O
of	O
5	O
years	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
6	O
-	O
7	O
.	O

3	O
years	O
)	O
.	O

Among	O
HPV	O
-	O
16	O
-	O
positive	O
HNSCC	O
cohort	O
,	O
T2DM	O
was	O
a	O
risk	O
for	O
poorer	O
prognosis	O
(	O
hazard	O
ratio	O
,	O
2	O
.	O
57	O
;	O
95	O
%	O
Cl	O
,	O
1	O
.	O
09	O
-	O
6	O
.	O

07	O
)	O
,	O
and	O
had	O
lower	O
median	O
survival	O
of	O
3	O
years	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
8	O
-	O
4	O
.	O

1	O
years	O
)	O
,	O
as	O
compared	O
to	O
6	O
years	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
8	O
-	O
9	O
.	O

1	O
years	O
)	O
in	O
non	O
-	O
T2DM	O
.	O
Patient	O
-	O
specific	O
factors	O
for	O
HPV	O
-	O
positive	O
HNSCC	O
are	O
T2DM	O
,	O
history	O
of	O
primary	O
HNSCC	O
and	O
tonsillar	O
site	O
.	O

T2DM	O
is	O
associated	O
with	O
poorer	O
prognosis	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
might	O
be	O
beneficial	O
if	O
routine	O
HPV	O
-	O
16	O
screening	O
is	O
carried	O
out	O
in	O
T2DM	O
patients	O
which	O
can	O
provide	O
better	O
therapeutic	O
and	O
management	O
strategies	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
UCLH	O
.	O

The	O
ethic	O
number	O
for	O
the	O
study	O
is	O
04	O
/	O
Q0505	O
/	O
59	O
by	O
National	O
Research	O
and	O
Ethics	O
Committee	O
(	O
NRES	O
)	O
London	O
-	O
Harrow	O
through	O
University	O
College	O
of	O
London	O
Hospitals	O
NHS	O
Foundation	O
Trust	O
.	O

Patients’	O
records	O
were	O
fully	O
anonymized	O
prior	O
to	O
access	O
.	O

Study	O
population	O

The	O
study	O
cohort	O
was	O
derived	O
from	O
the	O
head	O
and	O
neck	O
cancer	O
department	O
medical	O
records	O
at	O
University	O
College	O
of	O
London	O
Hospital	O
(	O
UCLH	O
)	O
.	O

Patients	B-Study_Cohort
diagnosed	I-Study_Cohort
with	I-Study_Cohort
HNSCC	I-Study_Cohort
between	O
January	B-Study_Time
1	I-Study_Time
,	I-Study_Time
2003	I-Study_Time
,	I-Study_Time
and	I-Study_Time
April	I-Study_Time
30	I-Study_Time
,	I-Study_Time
2015	I-Study_Time
,	O
at	O
UCLH	O
were	O
included	O
,	O
inclusive	O
.	O

Patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
older	O
than	O
18	O
years	O
and	O
were	O
newly	O
diagnosed	O
with	O
a	O
histological	O
confirmed	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
tonsils	O
,	O
hypopharynx	O
,	O
lar	O
-	O
ynx	O
,	O
nasopharynx	O
,	O
or	O
multiple	O
HNSCC	O
tumor	O
sites	O
.	O

Multiple	O
HNSCC	O
tumor	O
sites	O
was	O
defined	O
as	O
the	O
presence	O
of	O
two	O
or	O
more	O
tumors	O
synchronously	O
in	O
head	O
and	O
neck	O
region	O
.	O

Anatomic	O
site	O
of	O
the	O
tumor	O
was	O
determined	O
by	O
a	O
physical	O
examination	O
that	O
was	O
performed	O
by	O
the	O
treating	O
head	O
and	O
neck	O
surgeon	O
.	O

SPSS	O
file	O
consisting	O
of	O
all	O
patients’	O
parameters	O
used	O
in	O
model	O
predic	O
-	O
tion	O
for	O
the	O
study	O
is	O
provided	O
in	O
.	O

HPV	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
16	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique

The	O
outcome	O
of	O
interest	O
was	O
tumor	O
HPV	O
-	O
16	O
status	O
.	O

Patients	O
were	O
classified	O
as	O
having	O
a	O
diagno	O
-	O
sis	O
of	O
either	O
HPV	O
-	O
16	O
-	O
positive	O
or	O
HPV	O
-	O
16	O
-	O
negative	O
HNSCC	O
based	O
upon	O
HPV	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
16	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
detec	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
tion	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
formalin	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
fixed	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
paraffin	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
embedded	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
FFPE	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
tumors	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
approach	I-HPV_Lab_Technique
for	I-HPV_Lab_Technique
biotinylated	I-HPV_Lab_Technique
probes	I-HPV_Lab_Technique
[	O
]	O
.	O

Tissue	B-HPV_Sample_Type
consists	O
of	O
triplicate	O
tumor	O
cores	O
from	O
corre	O
-	O
sponding	O
FFPE	O
blocks	O
from	O
all	O
patients	O
were	O
constructed	O
.	O

The	O
positive	O
control	O
was	O
p16	B-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
and	O
the	O
negative	O
control	O
was	O
inflamed	O
tonsil	O
tissue	B-HPV_Sample_Type
.	O

Specific	O
staining	O
of	O
tumor	O
cell	O
nuclei	O
for	O
HPV	O
-	O
16	O
defined	O
a	O
positive	O
tumor	O
.	O

Univariate	O
analysis	O
of	O
variables	O

Patient	O
independent	O
variables	O
consisted	O
of	O
demographic	O
variables	O
,	O
including	O
age	O
and	O
sex	O
;	O
co	O
-	O
morbid	O
conditions	O
,	O
including	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
,	O
hypertension	O
,	O
vascular	O
dis	O
-	O
eases	O
,	O
previous	O
primary	O
HNSCC	O
,	O
history	O
of	O
current	O
or	O
former	O
smoking	O
,	O
or	O
alcohol	O
use	O
;	O
treat	O
-	O
ments	O
history	O
,	O
including	O
use	O
of	O
anti	O
-	O
hypertensives	O
,	O
hypoglycemic	O
agents	O
,	O
or	O
anti	O
-	O
infective	O
for	O
systemic	O
use	O
;	O
and	O
HNSCC	O
tumor	O
anatomic	O
sites	O
.	O

A	O
patient’s	O
co	O
-	O
morbid	O
conditions	O
and	O
treat	O
-	O
ment	O
history	O
were	O
categorized	O
as	O
present	O
or	O
absent	O
at	O
the	O
time	O
of	O
HNSCC	O
diagnosis	O
.	O

The	O
ana	O
-	O
tomic	O
sites	O
of	O
head	O
and	O
neck	O
included	O
in	O
the	O
analysis	O
were	O
oropharynx	O
,	O
tonsils	O
,	O
oral	O
cavity	O
,	O
larynx	O
,	O
hypopharynx	O
,	O
paranasal	O
sinus	O
,	O
and	O
nasopharynx	O
.	O

In	O
this	O
study	O
,	O
a	O
large	O
number	O
of	O
our	O
patients	O
(	O
36	O
%	O
)	O
were	O
diagnosed	O
with	O
HPV	O
-	O
positive	O
tonsillar	O
carcinoma	O
;	O
therefore	O
,	O
tonsils	O
which	O
is	O
a	O
part	O
of	O
the	O
oropharynx	O
anatomic	O
site	O
were	O
analyzed	O
separately	O
.	O

Oropharynx	O
included	O
tumor	O
in	O
soft	O
palate	O
and	O
uvula	O
.	O

All	O
selected	O
variables	O
were	O
tested	O
for	O
multi	O
co	O
-	O
linearity	O
to	O
avoid	O
any	O
strong	O
correlation	O
between	O
the	O
variables	O
.	O

The	O
presence	O
of	O
co	O
-	O
linearity	O
was	O
examined	O
by	O
the	O
evaluation	O
of	O
variance	O
inflation	O
factors	O
and	O
magnitude	O
of	O
standard	O
errors	O
.	O

Variables	O
with	O
more	O
than	O
30	O
%	O
missing	O
val	O
-	O
ues	O
were	O
not	O
included	O
in	O
the	O
analysis	O
.	O

All	O
other	O
missing	O
data	O
were	O
imputed	O
using	O
the	O
multiple	O
imputation	O
technique	O
using	O
SPSS	O
(	O
version	O
21	O
;	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

Multivariate	O
analysis	O
and	O
model	O
development	O

The	O
first	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
patient	O
-	O
specific	O
factors	O
associated	O
with	O
HPV	O
-	O
16–pos	O
-	O
itive	O
HNSCC	O
based	O
on	O
baseline	O
demographic	O
and	O
clinical	O
data	O
.	O

Therefore	O
,	O
we	O
developed	O
a	O
sequential	O
series	O
of	O
logistic	O
regression	O
models	O
using	O
HPV	O
-	O
16–positive	O
HNSCC	O
as	O
the	O
depen	O
-	O
dent	O
variable	O
(	O
)	O
.	O

We	O
used	O
a	O
combination	O
of	O
clinical	O
medical	O
guidance	O
and	O
forward	O
selec	O
-	O
tion	O
method	O
to	O
determine	O
variable	O
selection	O
[	O
,	O
]	O
.	O

Using	O
univariate	O
analysis	O
,	O
variables	O
not	O
associated	O
with	O
HPV	O
-	O
16–positive	O
HNSCC	O
(	O
P	O
>	O
0	O
.	O
10	O
)	O
were	O
excluded	O
from	O
further	O
analyses	O
.	O

Variables	O
were	O
then	O
entered	O
in	O
each	O
model	O
in	O
accordance	O
with	O
the	O
chronology	O
in	O
which	O
patient	O

The	O
flow	O
chart	O
of	O
study	O
methodology	O
.	O

Abbreviations	O
:	O
HNSCC	O
,	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
;	O
HPV	O
,	O
human	O
papillomavirus	O
,	O
T2DM	O
;	O
type	O
2	O
diabetes	O
mellitus	O
,	O
UCLH	O
,	O
University	O
College	O
of	O
London	O
Hospital	O
.	O

�A	O
significant	O
interaction	O
(	O
P	O
<	O
.	O
05	O
)	O
was	O
identified	O
between	O
the	O
oral	O
cavity	O
tumor	O
site	O
and	O
alcohol	O
use	O
;	O
therefore	O
,	O
to	O
remove	O
their	O
simultaneous	O
influence	O
both	O
were	O
added	O
to	O
the	O
final	O
model	O
.	O

demographic	O
and	O
clinical	O
data	O
were	O
available	O
at	O
the	O
time	O
of	O
HNSCC	O
diagnosis	O
.	O

Model	O
with	O
more	O
variables	O
or	O
with	O
greater	O
complexity	O
was	O
successively	O
compared	O
with	O
the	O
simple	O
ones	O
.	O

Using	O
this	O
approach	O
,	O
4	O
Models	O
were	O
generated	O
from	O
the	O
data	O
provided	O
.	O

Model	O
1	O
,	O
was	O
developed	O
by	O
adding	O
patient	O
demographics	O
(	O
age	O
and	O
male	O
sex	O
)	O
.	O

Model	O
2	O
,	O
was	O
developed	O
by	O
adding	O
patient	O
co	O
-	O
morbidities	O
(	O
T2DM	O
,	O
previous	O
HNSCC	O
,	O
and	O
alcohol	O
use	O
)	O
and	O
compared	O
with	O
model	O
1	O
.	O

Model	O
3	O
,	O
was	O
developed	O
by	O
adding	O
patient	O
HNSCC	O
tumor	O
anatomic	O
sites	O
(	O
tonsils	O
and	O
oral	O
cavity	O
)	O
and	O
compared	O
with	O
model	O
2	O
.	O

We	O
then	O
tested	O
for	O
interaction	O
effects	O
between	O
predictors	O
or	O
variables	O
retained	O
in	O
model	O
3	O
.	O

A	O
significant	O
interaction	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
identified	O
between	O
the	O
oral	O
cavity	O
tumor	O
site	O
and	O
alcohol	O
use	O
;	O
therefore	O
,	O
both	O
variables	O
were	O
added	O
to	O
the	O
final	O
model	O
(	O
Model	O
4	O
)	O
.	O

Model	O
performance	O
evaluation	O

Improvement	O
in	O
model	O
performance	O
through	O
the	O
addition	O
of	O
new	O
variables	O
in	O
multivariate	O
logistic	O
regression	O
models	O
was	O
tested	O
using	O
measures	O
of	O
discrimination	O
and	O
goodness	O
of	O
fit	O
.	O

The	O
discriminatory	O
power	O
of	O
each	O
model	O
was	O
assessed	O
using	O
concordance	O
statistics	O
(	O
C	O
statis	O
-	O
tics	O
)	O
.	O

Discrimination	O
refers	O
to	O
the	O
ability	O
of	O
a	O
model	O
to	O
clearly	O
distinguish	O
between	O
2	O
groups	O
of	O
outcomes	O
(	O
discriminate	O
between	O
the	O
HPV	O
-	O
16–positive	O
HNSCC	O
and	O
HPV	O
-	O
16–negative	O
HNSCC	O
patient	O
groups	O
)	O
and	O
can	O
range	O
from	O
0	O
.	O
5	O
(	O
no	O
discrimination	O
)	O
to	O
1	O
.	O
0	O
(	O
perfect	O
discrim	O
-	O
ination	O
)	O
[	O
,	O
]	O
.	O

The	O
overall	O
model	O
fit	O
for	O
sequential	O
models	O
was	O
compared	O
using	O
Akaike	O
Information	O
Criterion	O
(	O
AIC	O
)	O
,	O
which	O
considers	O
both	O
the	O
statistical	O
goodness	O
of	O
fit	O
and	O
the	O
number	O
of	O
variables	O
required	O
to	O
achieve	O
this	O
particular	O
degree	O
of	O
fit	O
by	O
imposing	O
a	O
penalty	O
for	O
increasing	O
the	O
number	O
of	O
variables	O
.	O

The	O
optimal	O
fitted	O
model	O
was	O
selected	O
by	O
the	O
mini	O
-	O
mum	O
value	O
of	O
AIC	O
[	O
]	O
.	O

We	O
used	O
AIC	O
over	O
the	O
BIC	O
(	O
Bayesian	O
Information	O
Criterion	O
)	O
because	O
selection	O
with	O
BIC	O
may	O
lead	O
to	O
“under	O
-	O
fitting	O
,	O
”	O
since	O
BIC	O
penalizes	O
larger	O
models	O
by	O
excluding	O
many	O
predictors	O
[	O
]	O
.	O

The	O
accuracy	O
of	O
the	O
final	O
model	O
was	O
evaluated	O
using	O
positive	O
predictive	O
value	O
(	O
percentage	O
of	O
truly	O
positive	O
among	O
those	O
predicted	O
HPV	O
-	O
positive	O
HNSCC	O
)	O
,	O
and	O
negative	O
predictive	O
value	O
(	O
percentage	O
of	O
truly	O
negative	O
among	O
those	O
predicted	O
HPV	O
-	O
positive	O
HNSCC	O
)	O
.	O

Sensitivity	O
(	O
percentage	O
predicted	O
positive	O
among	O
all	O
truly	O
positive	O
)	O
and	O
specificity	O
(	O
percentage	O
predicted	O
negative	O
among	O
all	O
truly	O
negative	O
)	O
were	O
also	O
calculated	O
.	O

Survival	O
analysis	O

The	O
second	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
median	O
survival	O
time	O
between	O
patients	O
with	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
tumors	O
during	O
the	O
follow	O
-	O
up	O
period	O
of	O
1	O
to	O
13	O
years	O
(	O
median	O
of	O
1	O
year	O
)	O
.	O

We	O
also	O
compared	O
the	O
median	O
survival	O
time	O
between	O
T2DM	O
and	O
non	O
-	O
T2DM	O
sub	O
-	O
groups	O
within	O
the	O
HPV	O
-	O
positive	O
HNSCC	O
cohort	O
.	O

The	O
survival	O
time	O
for	O
individual	O
patients	O
was	O
defined	O
as	O
the	O
time	O
from	O
diagnosis	O
of	O
HNSCC	O
to	O
the	O
date	O
of	O
death	O
from	O
any	O
cause	O
.	O

For	O
patients	O
who	O
did	O
not	O
die	O
,	O
they	O
were	O
censored	O
at	O
the	O
end	O
of	O
study	O
on	O
April	O
30	O
,	O
2015	O
.	O

Survival	O
probability	O
was	O
computed	O
with	O
a	O
Cox	O
proportional	O
hazards	O
model	O
and	O
the	O
resultant	O
cumulative	O
survival	O
probability	O
curve	O
was	O
plotted	O
.	O

Cox	O
proportional	O
hazards	O
model	O
was	O
adjusted	O
for	O
age	O
,	O
male	O
sex	O
,	O
alcohol	O
use	O
,	O
smoking	O
,	O
and	O
American	O
Society	O
of	O
Anesthesiologist	O
(	O
ASA	O
)	O
co	O
-	O
morbidity	O
score	O
[	O
]	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
SPSS	O
21	O
.	O
0	O
.	O

Categorical	O
variables	O
are	O
presented	O
herein	O
as	O
percentages	O
,	O
and	O
the	O
continuous	O
variable	O
(	O
age	O
)	O
are	O
presented	O
as	O
means	O
(	O
SDs	O
)	O
.	O

The	O
age	O
variable	O
was	O
assessed	O
for	O
normality	O
using	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
.	O

Comparisons	O
of	O
categorical	O
variables	O
were	O
performed	O
using	O
the	O
chi	O
-	O
square	O
(	O
χ2	O
)	O
test	O
or	O
Fisher	O
exact	O
test	O
.	O

A	O
finding	O
of	O

P	O
<	O
0	O
.	O
05	O
was	O
considered	O
indicative	O
of	O
a	O
statistically	O
significant	O
difference	O
for	O
all	O
tests	O
.	O

